Citations (7)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Lalit Kumar, Ranjit Kumar Sahoo, Sudhir Kumar, Annie K. Baa, Ghazal Tansir, Neha Pathak, Prabhat S. Malik, Om Dutt Sharma, Anisha Mathew, Ankit Jha, Ritu Gupta, Atul Sharma, Ahitagni Biswas, Rakesh Kumar, Sanjay Thulkar, Soumyaranjan Malik & Ashish Dutt. (2023) Autologous stem cell transplant for multiple myeloma: Impact of melphalan dose on the transplant outcome. Leukemia & Lymphoma 64:2, pages 378-387.
Read now
Read now
Articles from other publishers (6)
Côme Bommier, Alexis Talbot, Stéphanie Harel, Wendy Cuccuini, Laurence Gérard & Bertrand Arnulf. (2020) Exploratory analysis of intensified conditioning as first line treatment for patients with high risk multiple myeloma. Hematological Oncology 38:4, pages 517-522.
Crossref
Crossref
Sara Pourhassan Shamchi, Mahdi Zirakchian Zadeh, Brian Østergaard, Jennifer Kim, William Y. Raynor, Mohsen Khosravi, Raheleh Taghvaei, Anne L. Nielsen, Oke Gerke, Thomas J. Werner, Paw Holdgaard, Niels Abildgaard, Mona-Elisabeth Revheim, Poul Flemming Høilund-Carlsen & Abass Alavi. (2020) Brain glucose metabolism in patients with newly diagnosed multiple myeloma significantly decreases after high-dose chemotherapy followed by autologous stem cell transplantation. Nuclear Medicine Communications 41:3, pages 288-293.
Crossref
Crossref
M. Blanes, J. I. Lorenzo, P. Ribas, A. Jiménez, J. D. González, M. J. Cejalvo, C. Solano, A. Alegre & Javier de la Rubia. (2019) Intravenous busulfan plus melphalan versus melphalan alone as conditioning regimen for patients with multiple myeloma. Annals of Hematology 98:8, pages 2013-2015.
Crossref
Crossref
Qaiser Bashir, Peter F Thall, Denái R Milton, Patricia S Fox, Jitesh D Kawedia, Partow Kebriaei, Nina Shah, Krina Patel, Borje S Andersson, Yago L Nieto, Ben C Valdez, Simrit Parmar, Gabriela Rondon, Ruby Delgado, Chitra Hosing, Uday R Popat, Betul Oran, Stefan O Ciurea, Pei Lin, Donna M Weber, Sheeba K Thomas, Hans C Lee, Elisabet E Manasanch, Robert Z Orlowski, Loretta A Williams, Richard E Champlin & Muzaffar H Qazilbash. (2019) Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. The Lancet Haematology 6:5, pages e266-e275.
Crossref
Crossref
Sung-Hoon Jung, Je-Jung Lee, Jin Seok Kim, Chang-Ki Min, Kihyun Kim, Yunsuk Choi, Hyeon-Seok Eom, Young Don Joo, Sung-Hyun Kim, Jae-Yong Kwak, Hye Jin Kang, Jae Hoon Lee, Ho Sup Lee, Yeung-Chul Mun, Joon Ho Moon, Sang Kyun Sohn, Seong Kyu Park, Yong Park, Ho-Jin Shin & Sung-Soo Yoon. (2018) Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150). Biology of Blood and Marrow Transplantation 24:5, pages 923-929.
Crossref
Crossref
Maurizio Musso, Giuseppe Messina, Gianpaolo Marcacci, Alessandra Crescimanno, Giuseppe Console, Daniela Donnarumma, Renato Scalone, Antonio Pinto & Massimo Martino. (2015) High-Dose Melphalan Plus Thiotepa as Conditioning Regimen before Second Autologous Stem Cell Transplantation for “De Novo” Multiple Myeloma Patients: A Phase II Study. Biology of Blood and Marrow Transplantation 21:11, pages 1932-1938.
Crossref
Crossref